Developer docs
API playgroundTry for free, no card

Search company profiles

Johnson & Johnson Vision Care

Full company profile

uuid00061r9

Namestring
Johnson & Johnson Vision Care
Legal namestring
Johnson & Johnson Surgical Vision, Inc.
Websiteurl
jjvision.com
Company typeenum
Private
Founded yearint
1987
Descriptiontext

Johnson & Johnson Vision Care is the eye health division of Johnson & Johnson, operating through the legal entity Johnson & Johnson Surgical Vision, Inc. (incorporated in New York). The company develops, manufactures, and commercializes a comprehensive portfolio of eye health products spanning four franchises: contact lenses under the ACUVUE brand (including ACUVUE OASYS MAX 1-Day and ACUVUE Abiliti overnight ortho-k lenses for myopia management), intraocular lenses under the TECNIS brand for cataract surgery (Eyhance, PureSee, and Odyssey), personalized laser vision correction systems branded iLASIK with iDESIGN Refractive Studio wavefront-guided diagnostics, and the TearScience LipiFlow thermal pulsation system for Meibomian Gland Dysfunction-related dry eye. The franchise is described as a $5 billion global business unit and holds approximately 35–40% share of the global contact lens market.

The company serves patients across the life span—children requiring myopia management, adults seeking vision correction or laser refractive surgery, and seniors undergoing cataract surgery—through a B2B2C model. Products are sold primarily to eye care professionals (optometrists and ophthalmologists) who prescribe and dispense contact lenses to consumers, and directly to hospitals, ambulatory surgery centers, and specialized eye surgery practices that perform cataract and laser procedures. Revenue is generated through hardware sales of devices and consumables, with surgical pricing quote-based and consumer pricing set at retail. The company maintains patient-facing education websites, interactive tools such as myopia quizzes and LASIK cost calculators, a Find a Doctor locator, and a Sight For Kids partnership with Lions Clubs International Foundation that ties ACUVUE Abiliti purchases to pediatric eye exams.

Operations span North America (Jacksonville headquarters and US sales), Europe (Limerick, Ireland manufacturing), and Asia-Pacific (Japan, China, India), with stated global reach. The company is wholly owned by Johnson & Johnson (NYSE: JNJ) and does not have separate public financials, outside institutional ownership, or standalone capital structure.

Short descriptiontext

Johnson & Johnson Vision Care is the eye health division of Johnson & Johnson, developing and commercializing contact lenses (ACUVUE), intraocular lenses (TECNIS), laser vision correction systems (iLASIK), and dry eye treatments (LipiFlow) sold to eye care professionals and surgical centers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersJacksonville, United States
HQ citystring
Jacksonville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contact lens manufacturing, intraocular lens implants, laser vision correction, myopia management products, dry eye treatment devices
Industry4 codes
1Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
CodeHLAHAJAEPrimaryYes
2Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
CodeHLAHAJAHPrimaryNo
3Cornea, External Disease & Refractive Surgery (LASIK/PRK)
CodeHLAKAKAFPrimaryNo
4Contact Lens Specialty & Myopia Control
CodeHLAKAKAKPrimaryNo
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Ophthalmic Goods Merchant Wholesalers42346
SIC code2 codes
  • Ophthalmic Goods3851
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contact Lens Sales
TypeHardware Sales
Description

Sale of ACUVUE brand contact lenses including daily disposables, bi-weekly and monthly lenses, and specialty lenses for myopia management, astigmatism, and presbyopia. Products sold through eye care professionals who prescribe and fit lenses for patients.

jjvision.com
2Intraocular Lens (IOL) Sales
TypeHardware Sales
Description

Sale of TECNIS brand IOLs for cataract surgery, including monofocal, toric, and presbyopia-correcting lenses. Products sold to hospitals and surgical centers where ophthalmologists perform cataract procedures.

jjvision.com
3Laser Vision Correction Systems
TypeHardware Sales
Description

Sale and service of iLASIK surgical systems and consumables to eye surgery centers and hospitals. Includes iDESIGN diagnostic systems, STAR S4 IR excimer lasers, and iFS femtosecond lasers.

jjvision.com
4Dry Eye Treatment Devices
TypeHardware Sales
Description

Sale of TearScience LipiFlow and related diagnostic devices (LipiScan, LipiView) for diagnosis and treatment of Meibomian Gland Dysfunction to eye care practices.

jjvision.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Supply Chain
Pricing details1 tier
1iLASIK procedure cost varies by patient needs and geography
ModelOtherBilling cadencePay-as-you-go
Notes

The company provides a cost calculator tool to help patients estimate monthly costs of glasses/contacts versus laser vision correction. Actual procedure costs depend on individual prescriptions, geographic location, and specific technology used.

jjvision.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ACUVUE
Description

Brand of contact lenses including ACUVUE Oasys Max 1-Day, ACUVUE Abiliti Overnight therapeutic lenses for myopia management

jjvision.com
+3 more records
Core offering1 text field

Johnson & Johnson Vision Care manufactures and sells a comprehensive portfolio of eye health products, including ACUVUE brand contact lenses (daily disposables, reusable, and overnight ortho-k therapeutic lenses for myopia management), TECNIS brand intraocular lenses for cataract surgery, iLASIK laser vision correction systems with iDESIGN diagnostics, and TearScience LipiFlow devices for treating Meibomian Gland Dysfunction. Products are sold primarily through eye care professionals (optometrists, ophthalmologists) and surgical centers globally, with a market-leading 35-40% share of the global contact lens market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 9 out of 10 people see better after cataract surgery
+4 more records
Product overview1 text field

Johnson & Johnson Vision Care offers a comprehensive eye health portfolio spanning contact lenses, intraocular lenses (IOLs), laser vision correction, and dry eye treatments. The ACUVUE brand covers daily disposable and overnight therapeutic contact lenses for vision correction and myopia management. The TECNIS IOL family includes monofocal (Eyhance) and presbyopia-correcting (PureSee, Odyssey) lenses for cataract surgery. The iLASIK procedure with iDESIGN technology provides personalized laser vision correction. TearScience LipiFlow addresses meibomian gland dysfunction as a leading cause of dry eye. The company also supports the Sight For Kids CSR program providing eye exams to underserved children.

Product and service1 record
1TECNIS Eyhance IOL
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Johnson & Johnson Vision supports the Sight For Kids program, a corporate social responsibility initiative providing free comprehensive eye exams to children in need globally. The partnership leverages Lions Clubs International Foundation's community network to deliver eye health services. Each annual purchase of ACUVUE Abiliti products contributes funding for a free eye exam for a child in need. To date, the program has reached almost 48 million students globally with over 500,000 children receiving eyeglasses.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Alcon is the largest direct competitor to Johnson & Johnson Vision Care across contact lenses (Dailies, Air Optix, Precision), IOLs (PanOptix, Vivity), and surgical equipment. Both companies operate the same eye care professional channel and compete head-to-head for ophthalmology and optometry contracts globally.

TypeDirect peer
Description

Bausch + Lomb competes directly with ACUVUE in contact lenses (Biotrue, Ultra) and with TECNIS in IOLs (enVista, LuxSmart), while also offering ophthalmic surgical instruments and dry eye products. The company shares J&J Vision's ECP-led distribution model and premium vision care positioning.

TypeDirect peer
Description

CooperVision is a leading contact lens manufacturer (Biofinity, MyDay, clariti) competing with ACUVUE primarily in the reusable and specialty lens segments. The company is part of The Cooper Companies and focuses on contact lenses, making it a focused direct peer in J&J Vision's largest revenue category.

TypeBroad incumbent
Description

Carl Zeiss Meditec offers IOLs (CT LUCIA, CT SPHERIS), refractive laser systems (VisuMax, SMILE), and ophthalmic diagnostic equipment that compete with J&J Vision's TECNIS IOLs and iLASIK platforms. As a broader medical technology incumbent with deep optical heritage, Zeiss overlaps significantly in the surgical ophthalmology segment.

TypeDirect peer
Description

STAAR Surgical specializes in implantable collamer lenses (ICL/EVO) for refractive vision correction, competing with J&J Vision's iLASIK and premium IOL franchises in the elective vision correction market. Both companies serve ophthalmic surgeons performing refractive and cataract procedures.

TypeDirect peer
Description

HOYA's ophthalmic division manufactures IOLs (Vivinex, iSert) and contact lens-related products, competing directly with TECNIS IOLs in cataract surgery markets globally. HOYA also supplies optical lens blanks and related products used by ECPs.

TypeEmerging player
Description

Glaukos develops minimally invasive glaucoma surgery (MIGS) devices and sustained pharmaceutical delivery platforms for ophthalmic conditions. While not directly competing in J&J Vision's core segments, Glaukos represents an emerging player in the broader ophthalmic medical device space where J&J Vision could expand.

TypeEmerging player
Description

Sightglass Vision develops novel spectacle lenses and contact lenses for myopia management in children, directly competing with ACUVUE Abiliti in the childhood myopia segment. As a focused emerging player in myopia control, it represents both a competitive threat and a potential strategic target for J&J Vision.

TypeEmerging player
Description

Ocular Therapeutix develops sustained-release ophthalmic drug delivery products for post-surgical pain, allergic conjunctivitis, and other ocular conditions. The company operates in adjacent ophthalmic pharmaceutical and device markets that intersect with J&J Vision's surgical and dry eye franchises.

TypeEmerging player
Description

Lumenis (acquired by Boston Scientific) developed ophthalmic laser platforms including the OptiLight IPL device for dry eye treatment, competing with TearScience LipiFlow in the in-office dry eye treatment market. Both companies serve ophthalmology and optometry practices with therapeutic device systems.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Johnson & Johnson Vision Care

Ophthalmic Medical Devicesjjvision.com

Johnson & Johnson Vision Care is the eye health division of Johnson & Johnson, developing and commercializing contact lenses (ACUVUE), intraocular lenses (TECNIS), laser vision correction systems (iLASIK), and dry eye treatments (LipiFlow) sold to eye care professionals and surgical centers worldwide.

What Johnson & Johnson Vision Care does

Johnson & Johnson Vision Care is the eye health division of Johnson & Johnson, operating through the legal entity Johnson & Johnson Surgical Vision, Inc. (incorporated in New York). The company develops, manufactures, and commercializes a comprehensive portfolio of eye health products spanning four franchises: contact lenses under the ACUVUE brand (including ACUVUE OASYS MAX 1-Day and ACUVUE Abiliti overnight ortho-k lenses for myopia management), intraocular lenses under the TECNIS brand for cataract surgery (Eyhance, PureSee, and Odyssey), personalized laser vision correction systems branded iLASIK with iDESIGN Refractive Studio wavefront-guided diagnostics, and the TearScience LipiFlow thermal pulsation system for Meibomian Gland Dysfunction-related dry eye. The franchise is described as a $5 billion global business unit and holds approximately 35–40% share of the global contact lens market.

The company serves patients across the life span—children requiring myopia management, adults seeking vision correction or laser refractive surgery, and seniors undergoing cataract surgery—through a B2B2C model. Products are sold primarily to eye care professionals (optometrists and ophthalmologists) who prescribe and dispense contact lenses to consumers, and directly to hospitals, ambulatory surgery centers, and specialized eye surgery practices that perform cataract and laser procedures. Revenue is generated through hardware sales of devices and consumables, with surgical pricing quote-based and consumer pricing set at retail. The company maintains patient-facing education websites, interactive tools such as myopia quizzes and LASIK cost calculators, a Find a Doctor locator, and a Sight For Kids partnership with Lions Clubs International Foundation that ties ACUVUE Abiliti purchases to pediatric eye exams.

Operations span North America (Jacksonville headquarters and US sales), Europe (Limerick, Ireland manufacturing), and Asia-Pacific (Japan, China, India), with stated global reach. The company is wholly owned by Johnson & Johnson (NYSE: JNJ) and does not have separate public financials, outside institutional ownership, or standalone capital structure.

Johnson & Johnson Vision Care firmographics

Firmographics
Name
Johnson & Johnson Vision Care
Legal name
Johnson & Johnson Surgical Vision, Inc.
Website
https://jjvision.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Johnson & Johnson Vision Care is the eye health division of Johnson & Johnson, developing and commercializing contact lenses (ACUVUE), intraocular lenses (TECNIS), laser vision correction systems (iLASIK), and dry eye treatments (LipiFlow) sold to eye care professionals and surgical centers worldwide.
Ownership category
akta.pro rank

Johnson & Johnson Vision Care industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (42346)
SIC
Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE)
akta.pro secondary industries
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH), Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF), Contact Lens Specialty & Myopia Control (HLAKAKAK)

Keywords

  • Contact lens manufacturing
  • Intraocular lens implants
  • Laser vision correction
  • Myopia management products
  • Dry eye treatment devices

Where Johnson & Johnson Vision Care is headquartered

Location

Headquarters

HQ city
Jacksonville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Johnson & Johnson Vision Care business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain

Revenue model

  1. Contact Lens Sales: Sale of ACUVUE brand contact lenses including daily disposables, bi-weekly and monthly lenses, and specialty lenses for myopia management, astigmatism, and presbyopia. Products sold through eye care professionals who prescribe and fit lenses for patients.
  2. Intraocular Lens (IOL) Sales: Sale of TECNIS brand IOLs for cataract surgery, including monofocal, toric, and presbyopia-correcting lenses. Products sold to hospitals and surgical centers where ophthalmologists perform cataract procedures.
  3. Laser Vision Correction Systems: Sale and service of iLASIK surgical systems and consumables to eye surgery centers and hospitals. Includes iDESIGN diagnostic systems, STAR S4 IR excimer lasers, and iFS femtosecond lasers.
  4. Dry Eye Treatment Devices: Sale of TearScience LipiFlow and related diagnostic devices (LipiScan, LipiView) for diagnosis and treatment of Meibomian Gland Dysfunction to eye care practices.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goiLASIK procedure cost varies by patient needs and geography

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Johnson & Johnson Vision Care product offering

Product offering

Core offering

Johnson & Johnson Vision Care manufactures and sells a comprehensive portfolio of eye health products, including ACUVUE brand contact lenses (daily disposables, reusable, and overnight ortho-k therapeutic lenses for myopia management), TECNIS brand intraocular lenses for cataract surgery, iLASIK laser vision correction systems with iDESIGN diagnostics, and TearScience LipiFlow devices for treating Meibomian Gland Dysfunction. Products are sold primarily through eye care professionals (optometrists, ophthalmologists) and surgical centers globally, with a market-leading 35-40% share of the global contact lens market.

Product overview

Johnson & Johnson Vision Care offers a comprehensive eye health portfolio spanning contact lenses, intraocular lenses (IOLs), laser vision correction, and dry eye treatments. The ACUVUE brand covers daily disposable and overnight therapeutic contact lenses for vision correction and myopia management. The TECNIS IOL family includes monofocal (Eyhance) and presbyopia-correcting (PureSee, Odyssey) lenses for cataract surgery. The iLASIK procedure with iDESIGN technology provides personalized laser vision correction. TearScience LipiFlow addresses meibomian gland dysfunction as a leading cause of dry eye. The company also supports the Sight For Kids CSR program providing eye exams to underserved children.

Differentiator

Problem solved

Functional benefit

Brands

  • ACUVUE: Brand of contact lenses including ACUVUE Oasys Max 1-Day, ACUVUE Abiliti Overnight therapeutic lenses for myopia management
  • TECNIS
  • iLASIK
  • TearScience LipiFlow

Products and services

  • TECNIS Eyhance IOL

Quantifiable outcome

  • 9 out of 10 people see better after cataract surgery
  • +4 more outcomes

Companies that use Johnson & Johnson Vision Care

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles4 records

Johnson & Johnson Vision Care technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Johnson & Johnson Vision Care partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Lions Clubs International FoundationcoreOthersJohnson & Johnson Vision supports the Sight For Kids program, a corporate social responsibility initiative providing free comprehensive eye exams to children in need globally. The partnership leverages Lions Clubs International Foundation's community network to deliver eye health services. Each annual purchase of ACUVUE Abiliti products contributes funding for a free eye exam for a child in need. To date, the program has reached almost 48 million students globally with over 500,000 children receiving eyeglasses.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Johnson & Johnson Vision Care competitors and assessment

Company assessment

Direct peers

  • Alcon: Alcon is the largest direct competitor to Johnson & Johnson Vision Care across contact lenses (Dailies, Air Optix, Precision), IOLs (PanOptix, Vivity), and surgical equipment. Both companies operate the same eye care professional channel and compete head-to-head for ophthalmology and optometry contracts globally.
  • Bausch + Lomb: Bausch + Lomb competes directly with ACUVUE in contact lenses (Biotrue, Ultra) and with TECNIS in IOLs (enVista, LuxSmart), while also offering ophthalmic surgical instruments and dry eye products. The company shares J&J Vision's ECP-led distribution model and premium vision care positioning.
  • CooperVision: CooperVision is a leading contact lens manufacturer (Biofinity, MyDay, clariti) competing with ACUVUE primarily in the reusable and specialty lens segments. The company is part of The Cooper Companies and focuses on contact lenses, making it a focused direct peer in J&J Vision's largest revenue category.
  • STAAR Surgical: STAAR Surgical specializes in implantable collamer lenses (ICL/EVO) for refractive vision correction, competing with J&J Vision's iLASIK and premium IOL franchises in the elective vision correction market. Both companies serve ophthalmic surgeons performing refractive and cataract procedures.
  • HOYA Corporation: HOYA's ophthalmic division manufactures IOLs (Vivinex, iSert) and contact lens-related products, competing directly with TECNIS IOLs in cataract surgery markets globally. HOYA also supplies optical lens blanks and related products used by ECPs.

Broad incumbents

  • Carl Zeiss Meditec: Carl Zeiss Meditec offers IOLs (CT LUCIA, CT SPHERIS), refractive laser systems (VisuMax, SMILE), and ophthalmic diagnostic equipment that compete with J&J Vision's TECNIS IOLs and iLASIK platforms. As a broader medical technology incumbent with deep optical heritage, Zeiss overlaps significantly in the surgical ophthalmology segment.

Emerging players

  • Glaukos Corporation: Glaukos develops minimally invasive glaucoma surgery (MIGS) devices and sustained pharmaceutical delivery platforms for ophthalmic conditions. While not directly competing in J&J Vision's core segments, Glaukos represents an emerging player in the broader ophthalmic medical device space where J&J Vision could expand.
  • Sightglass Vision: Sightglass Vision develops novel spectacle lenses and contact lenses for myopia management in children, directly competing with ACUVUE Abiliti in the childhood myopia segment. As a focused emerging player in myopia control, it represents both a competitive threat and a potential strategic target for J&J Vision.
  • Ocular Therapeutix: Ocular Therapeutix develops sustained-release ophthalmic drug delivery products for post-surgical pain, allergic conjunctivitis, and other ocular conditions. The company operates in adjacent ophthalmic pharmaceutical and device markets that intersect with J&J Vision's surgical and dry eye franchises.
  • Lumenis: Lumenis (acquired by Boston Scientific) developed ophthalmic laser platforms including the OptiLight IPL device for dry eye treatment, competing with TearScience LipiFlow in the in-office dry eye treatment market. Both companies serve ophthalmology and optometry practices with therapeutic device systems.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Johnson & Johnson Vision Care social profiles

Digital presence

Johnson & Johnson Vision Care financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Johnson & Johnson Vision Care leadership team

Management profile

Number of profiles

Profiles5 records

Johnson & Johnson Vision Care funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Johnson & Johnson Vision Care M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Johnson & Johnson Vision Care

What does Johnson & Johnson Vision Care do?

Johnson & Johnson Vision Care manufactures and sells a comprehensive portfolio of eye health products, including ACUVUE brand contact lenses (daily disposables, reusable, and overnight ortho-k therapeutic lenses for myopia management), TECNIS brand intraocular lenses for cataract surgery, iLASIK laser vision correction systems with iDESIGN diagnostics, and TearScience LipiFlow devices for treating Meibomian Gland Dysfunction. Products are sold primarily through eye care professionals (optometrists, ophthalmologists) and surgical centers globally, with a market-leading 35-40% share of the global contact lens market.

Is Johnson & Johnson Vision Care a public or private company?

Johnson & Johnson Vision Care is a private company. It is classified as corporate owned and is currently operating.

When was Johnson & Johnson Vision Care founded?

Johnson & Johnson Vision Care was founded in 1987. It employs 1,001 to 5,000 people.

Where is Johnson & Johnson Vision Care based?

Johnson & Johnson Vision Care is headquartered in Jacksonville, United States, in the North America region.

How does Johnson & Johnson Vision Care make money?

Four revenue lines are on record. Contact Lens Sales are the primary driver. The others are intraocular Lens (IOL) Sales, laser Vision Correction Systems and dry Eye Treatment Devices.

Who are Johnson & Johnson Vision Care's main competitors?

Direct peers on record are Alcon, Bausch + Lomb, CooperVision, STAAR Surgical and HOYA Corporation. Carl Zeiss Meditec is listed as a broad incumbent. Emerging players are Glaukos Corporation, Sightglass Vision, Ocular Therapeutix and Lumenis.

Does Johnson & Johnson Vision Care have an API?

No public API is recorded for Johnson & Johnson Vision Care.

What industry is Johnson & Johnson Vision Care in?

Johnson & Johnson Vision Care's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAE, Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions), with a secondary code of HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerJohnson & Johnson Receives Ce Marking for Acuvue Oasys Max 2-Week Reusable Contact LensesJohnson & Johnson received CE marking for ACUVUE OASYS MAX 2-Week reusable contact lenses, featuring MAX technologies for comfort and clarity. The lens will launch in select European markets in late 2026, with broader rollout planned through 2028. It is not approved by the U.S. FDA and is not available in the United States.GurufocusJohnson & Johnson Receives CE Marking for ACUVUE OASYS MAX ReusaJohnson & Johnson received CE Marking for ACUVUE OASYS MAX 2-Week, a reusable contact lens with MAX technologies. The lens filters at least 60% of blue-violet light and is expected to launch in select European markets in late 2026, with broader rollout planned for 2027.Investing.comJohnson & Johnson receives CE mark for new 2-week contact lens By Investing.comJohnson & Johnson received CE Marking for ACUVUE OASYS MAX 2-Week contact lens, to roll out in select European countries later this year with wider rollout in 2027. The lens filters at least 60% of blue-violet light and is not approved by the U.S. FDA. Launch is phased starting late 2026, with expansion planned through 2028.Stock TitanJohnson & Johnson Receives CE Mark for 2-Week LensJohnson & Johnson received CE Marking for ACUVUE OASYS MAX 2-Week, a reusable contact lens with MAX technologies. The lens will launch in select European markets in late 2026, with broader rollout planned for 2027. It is not approved by the U.S. FDA and unavailable in the United States.PRLogGlobal Disposable Contact Lens MarketA market research report from Prophecy Market Insights projects the global disposable contact lens market to reach a specific valuation by 2029, growing at a stated CAGR. The analysis highlights key drivers such as FDA approvals for new technologies and regional growth in Asia Pacific due to rising disposable incomes. Major industry players identified in the competitive landscape include Johnson & Johnson, Alcon, and Bausch Health.PR NewswireTherapeutic Contact Lenses Market to Reach USD 35.2 Billion by 2036 Driven by Advanced Corneal Care, Drug Delivery Innovation, and Expanding Ophthalmic ProceduresFuture Market Insights released a market analysis projecting the global therapeutic contact lenses market to grow from USD 15.5 billion in 2025 to USD 35.2 billion by 2036, at a compound annual growth rate of 7.7%. Growth is driven by increasing adoption of bandage lenses and drug-eluting technologies for corneal protection, post-surgical recovery, and chronic eye disease management, supported by aging populations, rising diabetes-related ocular complications, and expanded digital device usage. Major industry players including Johnson & Johnson Vision Care, Alcon, CooperVision, and Bausch + Lomb are focusing on advanced silicone hydrogel materials, drug delivery innovations, and clinical validation to strengthen market positioning across hospital pharmacies and ophthalmology clinics.MoomooTherapeutic Contact Lenses Market to Reach USD 35.2 Billion by 2036 Driven by Advanced Corneal Care, Drug Delivery Innovation, and Expanding Ophthalmic ProceduresFuture Market Insights published a market analysis projecting the global therapeutic contact lenses market to grow from USD 15.5 billion in 2025 to USD 35.2 billion by 2036, representing a compound annual growth rate of 7.7%. Key growth drivers include rising chronic eye disorders, post-surgical applications, aging populations, and increased digital device usage. Major companies identified in the competitive landscape include Johnson & Johnson Vision Care, Alcon, CooperVision, Bausch + Lomb, and Menicon.RTE.ieEx-hurler's €1m payout from Johnson & Johnson cut by €58kJohnson & Johnson Vision Care (Ireland) successfully appealed a High Court award to former Limerick hurler Mark Keane, reducing his €944,000 payout by €58,000 to €886,000. The Court of Appeal found that the original award had double-counted damages by including €42,000 previously awarded for a 2014 road traffic accident and had miscalculated future earnings. The injury occurred in 2018 at the Johnson & Johnson plant in Plassey, Co Limerick, where Keane worked as a contact lens technician.American City Business JournalsJohnson & Johnson to invest $1 billion in Jacksonville expansionJohnson & Johnson announced a $1 billion investment in Jacksonville to expand its vision operations, including a new distribution facility. The company targets full operations by 2028, strengthening its U.S. supply chain for ACUVUE contact lenses. The project is part of a $55 billion U.S. investment through 2029.Global Market Insights Inc.North America Contact Lenses Market Size, ShareThe North America contact lenses market was valued at USD 4.6 billion in 2025 and is projected to reach USD 8.1 billion by 2035, growing at a compound annual growth rate of 5.8%, according to a report by Global Market Insights Inc. The United States dominates the regional market with a 91.4% share, driven by an aging population, rising prevalence of refractive errors, and strong adoption of advanced lens technologies. Key market players including Johnson & Johnson Vision Care, Alcon, CooperVision, Bausch + Lomb, and ABB Optical Group collectively held 88.7% market share in 2025, with recent product launches and parameter expansions reflecting ongoing innovation in daily disposables, silicone hydrogel materials, and specialty therapeutic lenses.